TY - JOUR
T1 - Mechanism of cytotoxic action of crambescidin-816 on human liver-derived tumour cells
AU - Rubiolo, J. A.
AU - Lõpez-Alonso, H.
AU - Roel, M.
AU - Vieytes, M. R.
AU - Thomas, O.
AU - Ternon, E.
AU - Vega, F. V.
AU - Botana, L. M.
N1 - Publisher Copyright:
© 2013 The British Pharmacological Society.
PY - 2014/4/1
Y1 - 2014/4/1
N2 - Background and Purpose Marine sponges have evolved the capacity to produce a series of very efficient chemicals to combat viruses, bacteria, and eukaryotic organisms. It has been demonstrated that several of these compounds have anti-neoplastic activity. The highly toxic sponge Crambe crambe has been the source of several molecules named crambescidins. Of these, crambescidin-816 has been shown to be cytotoxic for colon carcinoma cells. To further investigate the potential anti-carcinogenic effect of crambescidin-816, we analysed its effect on the transcription of HepG2 cells by microarray analysis followed by experiments guided by the results obtained. Experimental Approach After cytotoxicity determination, a transcriptomic analysis was performed to test the effect of crambescidin-816 on the liver-derived tumour cell HepG2. Based on the results obtained, we analysed the effect of crambescidin-816 on cell-cell adhesion, cell-matrix adhesion, and cell migration by Western blot, confocal microscopy, flow cytometry and transmission electron microscopy. Cytotoxicity and cell migration were also studied in a variety of other cell lines derived from human tumours. Key Results Crambescidin-816 had a cytotoxic effect on all the cell lines studied. It inhibited cell-cell adhesion, interfered with the formation of tight junctions, and cell-matrix adhesion, negatively affecting focal adhesions. It also altered the cytoskeleton dynamics. As a consequence of all these effects on cells crambescidin-816 inhibited cell migration. Conclusions and Implications The results indicate that crambescidin-816 is active against tumour cells and implicate a new mechanism for the anti-tumour effect of this compound.
AB - Background and Purpose Marine sponges have evolved the capacity to produce a series of very efficient chemicals to combat viruses, bacteria, and eukaryotic organisms. It has been demonstrated that several of these compounds have anti-neoplastic activity. The highly toxic sponge Crambe crambe has been the source of several molecules named crambescidins. Of these, crambescidin-816 has been shown to be cytotoxic for colon carcinoma cells. To further investigate the potential anti-carcinogenic effect of crambescidin-816, we analysed its effect on the transcription of HepG2 cells by microarray analysis followed by experiments guided by the results obtained. Experimental Approach After cytotoxicity determination, a transcriptomic analysis was performed to test the effect of crambescidin-816 on the liver-derived tumour cell HepG2. Based on the results obtained, we analysed the effect of crambescidin-816 on cell-cell adhesion, cell-matrix adhesion, and cell migration by Western blot, confocal microscopy, flow cytometry and transmission electron microscopy. Cytotoxicity and cell migration were also studied in a variety of other cell lines derived from human tumours. Key Results Crambescidin-816 had a cytotoxic effect on all the cell lines studied. It inhibited cell-cell adhesion, interfered with the formation of tight junctions, and cell-matrix adhesion, negatively affecting focal adhesions. It also altered the cytoskeleton dynamics. As a consequence of all these effects on cells crambescidin-816 inhibited cell migration. Conclusions and Implications The results indicate that crambescidin-816 is active against tumour cells and implicate a new mechanism for the anti-tumour effect of this compound.
KW - crambescidin-816
KW - transcriptomic analysis
KW - tumour cell adhesion
KW - tumour cell migration
KW - tumour cell viability
UR - http://www.scopus.com/inward/record.url?scp=84908876040&partnerID=8YFLogxK
U2 - 10.1111/bph.12552
DO - 10.1111/bph.12552
M3 - Article
C2 - 24328908
AN - SCOPUS:84908876040
SN - 0007-1188
VL - 171
SP - 1655
EP - 1667
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 7
ER -